Nurse-led Medication Self-management Intervention in the Improvement of Medication Adherence
Launched by HAMAD MEDICAL CORPORATION · Dec 7, 2022
Trial Information
Current as of February 05, 2025
Unknown status
Keywords
ClinConnect Summary
In terms of intervention we are giving six weeks motivational training ( 3 face face session and 2 telephonic follow ups).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • +18 years old or over,
- • Patients with at least two of the identified comorbidities (Hypertension, Chronic painful condition, Cancer, Inflammatory connective tissue disorders, Diabetes, Lipid disorder, Dyspepsia and gastroenteritis, Heart disease, Chronic obstructive pulmonary disease, Stroke and cerebrovascular disease , chronic kidney disorder , Asthma Thyroid disorders, Anemia, Chronic liver disease, Depression, Epilepsy, Anxiety \& other stress related disorders), (3) having at least one medication prescribed for a chronic condition over at least the 3 months prior to inclusion in the study,
- • Non-adherence to medications, as defined by scoring zero on the 8-item Medication Adherence Report Scale (Morisky -8)(29),
- • Independently managing their medications (i.e., not rely on a care taker),
- • Able to speak or understand English/Arabic,
- • Able and willing to receive phone calls, and
- • Capable of providing a written informed consent to participate in the study.
- Exclusion Criteria:
- • Being institutionalized in a long-term care facility,
- • Planning to move away from the community in the next 6 months,
- • Cognitive impairment (Mini-cog scores \< 4), and
- • Currently participating in research involving chronic disease management. Patients with cognitive impairment are excluded because they may not be able to provide valid answers to the questionnaires.
About Hamad Medical Corporation
Hamad Medical Corporation (HMC) is a leading healthcare provider in Qatar, dedicated to delivering high-quality medical services and advancing clinical research. As a prominent sponsor of clinical trials, HMC focuses on innovative healthcare solutions that enhance patient outcomes and contribute to the global medical knowledge base. With a robust infrastructure and a commitment to ethical research practices, HMC collaborates with local and international partners to conduct trials across various therapeutic areas, aiming to address pressing health challenges and improve the standard of care within the community. Through its research initiatives, HMC strives to foster a culture of scientific inquiry and evidence-based medicine, ultimately benefiting patients and the healthcare system at large.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials